Plexxikon
21
0
0
12
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
42.9%
9 terminated/withdrawn out of 21 trials
57.1%
-29.4% vs industry average
0%
0 trials in Phase 3/4
108%
13 of 12 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (21)
CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors
Role: collaborator
Novel BET Inhibitor PLX51107 for Steroid-Refractory Acute GVHD
Role: collaborator
Safety Study of PLX108-01 in Patients With Solid Tumors
Role: collaborator
Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers
Role: collaborator
A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
Role: collaborator
Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer
Role: collaborator
Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors
Role: collaborator
A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma
Role: collaborator
Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma
Role: collaborator
A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma
Role: collaborator
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
Role: collaborator
Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC)
Role: collaborator
A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma
Role: collaborator
Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Role: collaborator
A Study of PLX51107 in Advanced Malignancies
Role: lead
Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors
Role: lead
A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor
Role: lead
Safety Study of PLX4032 in Patients With Solid Tumors
Role: lead
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PLX5622 in Healthy Adult Volunteers
Role: lead
Safety, Pharmacokinetic (PK), Pharmcodynamic (PD), and Drug-Drug Interaction of PLX3397 in Patients With Rheumatoid Arthritis Who Are Receiving Methotrexate
Role: lead